Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways.

Cui, Tengjiao et al.·Oncotarget·2016·
RPEP-029052016RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

The GHRH analogs MR-409 and MR-502 significantly increased proliferation of human dermal fibroblasts by over 50% in vitro and improved cell survival under stress. MR-409 applied topically in vivo accelerated wound closure in a dose-dependent manner and reduced fibrosis, acting through MEK/ERK and PI3K/AKT pathways independent of IGF-1 receptor signaling.

Key Numbers

How They Did This

The study used in vitro experiments with primary human dermal fibroblasts to assess proliferation and survival after treatment with GHRH analogs MR-409 and MR-502. In vivo wound healing was evaluated by topical application of MR-409 on animal models, with histological analysis of wound contraction and fibrosis.

Why This Research Matters

Finding agents that promote fibroblast growth and survival can improve wound healing outcomes. These GHRH analogs resist degradation and activate key cell survival pathways, making them promising candidates for therapeutic development.

What This Study Doesn't Tell Us

The study does not specify the clinical trial phase or long-term safety data. The animal model results may not fully translate to humans without further testing.

Trust & Context

Original Title:
Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways.
Published In:
Oncotarget, 7(33), 52661-52672 (2016)
Database ID:
RPEP-02905

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-02905·https://rethinkpeptides.com/research/RPEP-02905

APA

Cui, Tengjiao; Jimenez, Joaquin J; Block, Norman L; Badiavas, Evangelos V; Rodriguez-Menocal, Luis; Vila Granda, Ailin; Cai, Renzhi; Sha, Wei; Zarandi, Marta; Perez, Roberto; Schally, Andrew V. (2016). Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways.. Oncotarget, 7(33), 52661-52672. https://doi.org/10.18632/oncotarget.11024

MLA

Cui, Tengjiao, et al. "Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways.." Oncotarget, 2016. https://doi.org/10.18632/oncotarget.11024

RethinkPeptides

RethinkPeptides Research Database. "Agonistic analogs of growth hormone releasing hormone (GHRH)..." RPEP-02905. Retrieved from https://rethinkpeptides.com/research/cui-2016-agonistic-analogs-of-growth

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.